Screener
Corcept Therapeutics CORT Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 53,890 | 60,471 | 120,155 | 121,206 |
| Selling, general and administrative | 156,896 | 103,851 | 302,252 | 194,511 |
| Total operating expenses | 214,847 | 167,755 | 429,351 | 321,553 |
| Income (loss) from operations | 41,300 | 26,675 | (8,301) | 30,091 |
| Interest and other income | 4,631 | 5,017 | 9,517 | 11,219 |
| Income before income taxes | 45,931 | 31,692 | 1,216 | 41,310 |
| Income tax (expense) benefit | (2,944) | 3,457 | 10,010 | 14,386 |
| Net income | 42,987 | 35,149 | 11,226 | 55,696 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's operating income?
- Corcept Therapeutics (CORT) reported operating income of $41.3M in Q2 2026.
- How has Corcept Therapeutics's operating income changed year-over-year?
- Corcept Therapeutics's operating income increased by 54.8% year-over-year, from $26.68M to $41.3M.
- What is the long-term trend for Corcept Therapeutics's operating income?
- Over 4 years (2021 to 2025), Corcept Therapeutics's operating income has grown at a -22.5% compound annual growth rate (CAGR), from $124.48M to $44.8M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Corcept Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude